Features | Partner Sites | Information | LinkXpress
Sign In
PZ HTL SA
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

Standardized Assays Developed to Quantify Human Proteins

By BiotechDaily International staff writers
Posted on 30 Dec 2013
Image: Orbitrap Velos Pro hybrid ion trap mass spectrometer (Photo courtesy of Thermo Scientific).
Image: Orbitrap Velos Pro hybrid ion trap mass spectrometer (Photo courtesy of Thermo Scientific).
The feasibility of large-scale standardized protein measurements, which are necessary for validation of disease biomarkers, has been developed.

Multiple reaction monitoring (MRM) mass spectrometry has been successfully applied to monitor targeted proteins in biological specimens, raising the possibility that assays could be configured to measure all human proteins.

Scientists at the Fred Hutchinson Cancer Research Center (Seattle, WA, USA) in collaboration with other intuitions targeted a protein-detection approach that has the potential to systematically and reliably measure the entire human repertoire of proteins, known as the proteome. The MRM technique can simultaneously and precisely detect the abundance of hundreds of proteins in many different samples. The teams of investigators were able to reproduce measurements of 319 proteins from human breast cancer cells, showing that the method can be standardized across laboratory and international boundaries.

This method enabled highly specific, precise, multiplex, quantification of a minimum of 170 proteins in 20 clinical samples per instrument per day— no other existing technology has this power. Because the mass spectrometry technique is targeted, meaning the scientists can tune the instruments to look for a specific subset of proteins in cancer cells or other sample types, it can detect the presence of proteins of interest at much lower levels in minute blood samples or biopsies than a nontargeted tactic.

Amanda Paulovich, MD, the senior author of the study, said, “This method has the potential to completely revolutionize how we measure human proteins. Having a global resource for standardized quantification of all human proteins would set new standards that would undoubtedly increase the reproducibility of preclinical research, which would have a dramatic impact on the translation of novel therapeutics and diagnostics. Right now, you can't make robust measurements of most human proteins. More than 10 years after the human genome has been sequenced and we have the full catalog of molecules as important as proteins, we still can't study the human proteome with any kind of throughput in a standardized, quantitative manner.” The study was published on December 8, 2013, in the journal Nature Methods.

Related Links:

Fred Hutchinson Cancer Research Center



comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: This novel, flexible film that can react to light is a promising step toward an artificial retina (Photo courtesy of the American Chemical Society).

Novel Nanofilm May Be Artificial Retina Precursor

Researchers have used advanced nanotechnology techniques to develop a light-sensitive film that has potential for future artificial retina applications. Investigators at the Hebrew University of Jerusalem... Read more

Drug Discovery

view channel
Image: Disruption and removal of malaria parasites by the experimental drug (+)-SJ733 (Photo courtesy of the University of California, San Francisco).

Experimental Antimalaria Drug Induces the Immune System to Destroy Infected Red Blood Cells

An experimental drug for the treatment of malaria was found to induce morphological changes in infected erythrocytes that enabled the immune system to recognize and eliminate them. Investigators at... Read more

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more

Business

view channel

R&D Partnership Initiated to Reduce Development Time for New Drugs

nanoPET Pharma, GmbH (Berlin, Germany) signed an open-ended framework contract with the international pharmaceutical company Boehringer Ingelheim (Ridgefield, CT, USA). By developing customized contrast agents for research in both basic and preclinical studies, nanoPET Pharma will contribute to the enhancement of Boehringer... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.